Ad-hoc | 24 April 2002 08:31

DEWB AG english

DEWB acquires 35 percent of the shares in Dr. Gottschall INSTRUCTION GmbH Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– DEWB acquires 35 percent of the shares in Dr. Gottschall INSTRUCTION GmbH The quoted Venture Capital company DEWB AG (Deutsche Effecten- und Wechsel- Beteiligungsgesellschaft) is further expanding its portfolio and taking a 35.24 percent stake in Dr. Gottschall INSTRUCTION GmbH. The start-up financing for the Ludwigshafen-based company is the first new investment by DEWB in the current business year. The portfolio now holds 38 investments. The firm of Dr. Gottschall INSTRUCTION GmbH has developed a platform technology with which pharmaceutical companies are now able to bring new active agents into marketable commodity more quickly and more cost-effectively. The active agent sets a specific reaction in motion, for example by attaching itself to a special protein. Consequently, the active agent has to ‘fit’ the protein like the key to a specific lock. INSTRUCTION artificially reproduces the structure of these proteins. This creates three-dimensional polymer receptors which are able to identify and bond to substances on a targeted basis. They virtually have a memory and recognise the matching substance every time there is contact. The pharmaceuticals industry is able to utilise this platform technology in order to identify promising candidates for active agents in their substance libraries. The advantage of the INSTRUCTION platform technology over other methods lies in the fact that an increased number of higher quality active agents can be identified with greater precision. The company’s product range covers the development of special polymers and services for drug development on the basis of lead substances which have already been identified. The platform technology of INSTRUCTION has been secured through national and international patents to protect it from potential competitors for several years. The firm of Dr. Gottschall INSTRUCTION GmbH, formed in 1997, sees itself as a partner to the pharmaceuticals industry and currently employs nine personnel, most of these with expertise in chemicals. The company has already cooperation agreements with the Anglo-Swedish AstraZeneca Plc and the German firm of Schwabe GmbH. Contact: Steffen Schneider, DEWB AG, Investor Relations Telephone / Telefax: ++49 3641 65 22 90 / 65 36 29 E-Mail: steffen.schneider@dewb-vc.com, Internet: http://www.dewb-vc.com end of ad-hoc-announcement (c)DGAP 24.04.2002 ——————————————————————————– WKN: 804100; ISIN: DE0008041005; Index: Listed: Amtlicher Handel in Berlin und Frankfurt 240831 Apr 02